Ruben de Kanter

Novel S1P(1) receptor agonists--part 3: from thiophenes to pyridines.

R. de Kanter, M. Bolli, Stefan Abele, 2014, Journal of medicinal chemistry.

Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction

R. de Kanter, G. Groothuis, M. Martignoni, 2006, Expert opinion on drug metabolism & toxicology.

Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent, and Selective Covalent Oral Inhibitor of KRASG12C

N. Ostermann, C. Schnell, Toshio Shimizu, 2022, Cancer discovery.

Induction of drug metabolizing enzymes: a survey of in vitro methodologies and interpretations used in the pharmaceutical industry--do they comply with FDA recommendations?

Nicola J Hewitt, R. de Kanter, N. Hewitt, 2007, Chemico-biological interactions.

Novel in vivo active anti-malarials based on a hydroxy-ethyl-amine scaffold.

R. de Kanter, S. Wittlin, C. Boss, 2013, Bioorganic & medicinal chemistry letters.

Discovery of the Clinical Candidate IDOR-1117-2520: A Potent and Selective Antagonist of CCR6 for Autoimmune Diseases.

C. Gnerre, S. Richard-Bildstein, M. Murphy, 2024, Journal of medicinal chemistry.

Characterization of Novel Antimalarial Compound ACT-451840: Preclinical Assessment of Activity and Dose–Efficacy Modeling

R. Price, D. Fidock, R. Sinden, 2016, PLoS medicine.

Novel S1P1 receptor agonists - Part 4: Alkylaminomethyl substituted aryl head groups.

R. de Kanter, M. Bolli, C. Kohl, 2016, European journal of medicinal chemistry.

Assessment of drug metabolism enzyme and transporter pharmacogenetics in drug discovery and early development: perspectives of the I-PWG.

R. Evers, L. Tremaine, R. de Kanter, 2016, Pharmacogenomics.